Table 7 (abstract P189). Patient characteristics
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two
cSLE n = 111 | SLE n = 40 | p* | |
|---|---|---|---|
Female | 91% (101/111) | 93% (37/40) | |
Ethnicity | |||
White | 69% (77/111) | 68% (27/40) | |
Non White | 31% (34/111) | 32% (13/40) | |
Age at study visit (median (range)) | 33 (18 – 65) | 40 (25 – 76) | p = 0.000 |
Age at diagnosis in yrs (median (range)) | 14 (4 – 17) | 28 (18 – 69) | p = 0.000 |
Disease duration in yrs (median (range)) | 20 (1 – 55) | 11 (1 – 34) | p = 0.000 |
Current SLEDAI-2 K score (median (range)) | 4 (0 – 14) | 4 (0 – 10) | |
SDI-score (median (range)) | 1 (0 – 8) | 1 (0 – 7) | |
Patients with SLICC-DI ≥ 1 | 62% (69/111) | 60% (24/40) | p = 0.05 |
Musculoskeletal | 41% (28/69) | 46% (11/24) | p = 0.027 |
Renal | 23% (16/69) | 8% (2/24) | |
Neuropsychiatric | 33%(23/69) | 13% (3/24) | |
Cardiovascular | 13% (9/69) | 33% (8/24) | |
Patients currently using any immunosuppressive drug | 87% (97/111) | 93% (37/40) | |
Current prednisone use | 60% (58/97) | 59% (22/37) | |
Renal involvement (ever) | 60% (67/111) | 48% (19/40) | |
Renal damage on SDI | 24% (16/67) | 11% (2/19) | n.s. |
Neuropsychiatric involvement (ever) | 41% (45/111) | 30% (12/40) | n.s. |
Neuropsychiatric damage on SDI | 51% (23/45) | 25% (3/12) | |
Myocardial infarction | 5% (5/111) | 3% (1/40) | |
Cerebrovascular accident | 6% (7/111) | 3% (1/40) | |